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Placenta accreta defines abnormal adherence of
the placenta to the uterine wall. The histology is
characterized by the presence of chorionic villi
directly attached to the myometrium. The exact
aetiology is unclear, but is thought to involve
absence of the decidua basalis and incomplete
development of the fibrinoid layer. The degree of
placental invasion allows the condition to be
histologically classified; placenta increta implies
the invasion of the myometrium by chorionic villi,
and placenta percreta the penetration by chorionic
villi through the myometrium and beyond the
uterine serosa.1 Placenta accreta is a rare condition
with an estimated incidence ranging from 1:540 to
1:93,000.2 We report a case of placenta accreta in
an otherwise uncomplicated pregnancy, that was
followed up by postnatal MRI. The mother under-
went treatment with methotrexate, and we
describe the MRI appearances before and after
chemotherapy administration.Case report
A 20-year-old woman with one previous normal
vaginal delivery presented with a retained placenta
in the third stage of her second delivery. She had
had an uncomplicated pregnancy and had no
documented obstetric risk factors normally associ-
ated with increased risk of placenta accreta. She
underwent augmentation of labour for prolonged
ruptured membranes at 40 weeks’ gestation. The
labour progressed normally, with the delivery of a
male infant. Despite an active third stage of labour,1477-6804/$ - see front matter Q 2005 Published by Elsevier Ltd on
doi:10.1016/j.cradex.2005.04.001
* Guarantor and correspondent: A. Rahman, Radiology Depart-
ment, Hull and East Yorkshire Hospitals, Anlaby Road, Hull
HU3 2JX, UK. Tel.:C44 1482 649558; fax:C44 1482 675709.
E-mail address: ayesha73uk@yahoo.co.uk (A. Rahman).the mother had a retained placenta and was taken
to theatre for manual removal. The placenta was
partially removed piecemeal, but morbid adher-
ence to the myometrium was suspected because no
clear plane of separation could be determined, and
the procedure was abandoned. The woman was
haemodynamically stable with minimal vaginal
bleeding, and thus commenced intravenous anti-
biotics. She was referred for MRI to assess the
placenta, including degree of invasion, before
consideration of the management options.
MRI was performed at 1.5T (GE Sigma LX,
Milwaukee, USA) using a pelvic phased array coil
for signal reception; buscopan, 20 mg IV, was
administered to minimize peristaltic artefact.
T2-W FSE images of the pelvis were acquired
sagittally, axially and obliquely perpendicular to
the uterine axis, using the following parameters:
TR 6000; TE 97.3/Ef; FOV 28!28; matrix 320!256;
section thickness/gapZ3/1 mm. Placental tissue
was clearly identified at the fundus and in the body
of the uterus, extending over approximately an 8-
cm length, demonstrating heterogeneous but pre-
dominantly bright signal intensity on T2W imaging.
There was good demarcation of much of the
placenta from the surrounding myometrium, but
the myometrium at the fundus was considerably
thinned and in places not separately visualized from
the placenta (Fig. 1). In a normally situated
placenta, there is a definite observable myometrial
layer present throughout. Implantation abnormality
of the placenta was diagnosed on the basis of
extreme thinning of the myometrium and, in
places, complete obliteration of the low signal
intensity of the myometrium. The serosal surface
appeared intact, and no abnormality of the sur-
rounding soft tissue was seen. These features were
consistent with placenta accreta.
Management options were discussed with the
woman and her family, and it was decided that, in
view of the minimal vaginal bleeding and her ageClinical Radiology Extra (2005) 60, 65–67behalf of The Royal College of Radiologists.
Figure 1 T2W sagittal MRI of the uterus showing
placental tissue of predominantly high signal in the
fundus. The arrow points to the extreme thinning and in
places absence of the low-signal myometrial layer.
Figure 2 T2W axial MRI of the same case as Fig. 1,
showing decrease in size of the placental tissue and a
striking change to low signal intensity. The arrow points
to the irregularity of the placental–myometrial interface,
indicative of continuing myometrial invasion.
Figure 3 T2W axial MRI showing a uterus of normal size,
with normal internal anatomy.
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ate. She received methotrexate, 31 mg (1/2 mg/kg)
IM, and folinic acid 15 mg, on alternate days for
5 days. She was carefully monitored for vaginal
bleeding and sepsis, and completed a 2-week
course of ciprofloxacin and metronidazole.
Following treatment, MRI was repeated. Using
the same parameters, T2W FSE images were
acquired sagittally and axially through the pelvis
and further axial T2W FSE images through the
abdomen were added. The previously noted pla-
cental mass had decreased in size to a maximum of
5 cm. There was striking alteration in signal
intensity on T2W images, with the lesion now
primarily of low signal intensity and only scattered
areas of high signal intensity (Fig. 2). The lesion
continued to produce considerable thinning of
overlying myometrium, as seen on the previous
study. The thinning and irregularity of the interface
between mass and myometrium was considered
indicative of continuing myometrial invasion, and
the altered signal intensitywas attributed to reduced
vascularity, possibly with associated fibrosis.
The woman remained clinically well, and follow-
ing counselling and a negative serum bHCG, had a 3-
year contraceptive implant fitted. Further imaging
was planned for 3 months later. About 10 days
before the third MR study, the patient experienced
acute-onset lower pelvic pain similar to labour
pains and passed a fleshy mass, which was sub-
mitted for histopathology. Subsequent MRI showedthe uterus to be of normal size and internal
anatomy, with no focal signal intensity changes or
mass lesions (Fig. 3). Histology confirmed placental
tissue with infarction and calcification.
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Placenta accreta is a rare condition that can occur
with placenta praevia or, as in this case, with a
normally situated placenta. When the condition
arises in a normally situated placenta, it is very
rarely suspected antenatally. Diagnosis usually is
made during manual removal of the placenta.3
Placenta praevia may predispose to the develop-
ment of placenta accreta because of the
inadequate decidual response of the lower uterine
segment.4 Trophoblastic invasion may be further
enhanced by previous disruption of the myome-
trium by uterine scarring due to either caesarean
section or curettage. Clarke and colleagues found
that the frequency of placenta accreta in the
presence of placenta praevia increased from 24%
after one caesarean section to 67% after four or
more caesarean sections.5 Although there is much
evidence to support the known risk factors for
placenta accreta, in the case described no such
features were identified. Gielchinsky and col-
leagues found that 20% of cases of placenta accrete
occurred in primiparous women without any known
risk factors.6 A possible explanation in this clinical
setting is subclinical endometrial infection.
Placenta accreta and its variants result in
substantial intrapartum morbidity and mortality.7
Prenatal diagnosis is crucial for appropriate coun-
selling and surgical planning.8 Although hyster-
ectomy is a recommended treatment,
conservative management should be considered
for women desiring a future pregnancy and whose
vaginal bleeding is not excessive.4 The successful
use of methotrexate in the conservative manage-
ment of placenta accreta was first described by
Arulkumaran et al. in 1986,9 and subsequently by
others.10,11 However, no standard protocols exist.
Methotrexate is a folate antagonist and affects
placental tissue by decreasing vascularity, which in
turn leads to necrosis, as in our case. The
antimetabolite specifically targets chorionic tissue,
and has been used in the treatment of gestational
trophoblastic malignancies. To our knowledge, this
is the first report in the literature of sequential MRI
before, during and after methotrexate
administration.
The roles of US and MRI in diagnosis have been
studied by various authors.12,13 MRI offers multi-
planar capability and excellent soft-tissueresolution. It depends on neither operator nor
patient. Although Lam et al.14 have found MRI and
US to have poor predictive value in the diagnosis of
placenta accreta, most workers have found MRI to
be a valuable complement to US when additional
information is needed to make treatment decisions
during pregnancy. In our case, antenatal US did not
establish the diagnosis. This might have been due in
part to the fundal location as well as the low clinical
suspicion. MRI played an essential role, allowing
appropriate conservative management of this case.References
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